PFG
LGND icon

PAX Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

PAX Financial Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,361
Closed -$446K – 187
2022
Q1 		$446K Buy
+6,361
New +$462K 0.1% 144

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

PAX Financial Group's LGND Position: Q2 2022 in Review

PAX Financial Group sold out of Ligand Pharmaceuticals (LGND) in Q2 2022, closing a stake of 6,361 shares — an estimated $446K sold.

PAX Financial Group first reported a position in LGND in Q1 2022 and held it in 1 quarter. The position peaked at $446K in Q1 2022. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.

  • PAX Financial Group reported no remaining Ligand Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • PAX Financial Group sold 6,361 Ligand Pharmaceuticals shares in Q2 2022, an estimated $446K.
  • PAX Financial Group first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • PAX Financial Group's Ligand Pharmaceuticals position peaked at $446K in Q1 2022.
  • 197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.

Based on PAX Financial Group's 13F filing for Q2 2022, filed 9 Aug 2022.